Guardian Pharmacy Services (GRDN)
Market Price (1/21/2026): $28.3 | Market Cap: $1.8 BilSector: Health Care | Industry: Health Care Facilities
Guardian Pharmacy Services (GRDN)
Market Price (1/21/2026): $28.3Market Cap: $1.8 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Low stock price volatilityVol 12M is 46% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 30x, P/EPrice/Earnings or Price/(Net Income) is 44x |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more. | Key risksGRDN key risks include [1] margin compression from inflation due to its inability to raise prices for customers whose reimbursements are dictated by the government and PBMs, Show more. |
| Low stock price volatilityVol 12M is 46% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more. |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 30x, P/EPrice/Earnings or Price/(Net Income) is 44x |
| Key risksGRDN key risks include [1] margin compression from inflation due to its inability to raise prices for customers whose reimbursements are dictated by the government and PBMs, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Guardian Pharmacy Services (GRDN) stock has gained about 10% since 9/30/2025 because of the following key factors:
1. Strong Q3 2025 Financial Performance: Guardian Pharmacy Services reported robust third-quarter 2025 results on November 10, 2025, with revenue of $377.4 million, a 20% increase year-over-year, exceeding analyst expectations. The company also saw its adjusted EBITDA grow by 19% to $27.3 million, and its resident count increased by 13% to approximately 204,000. These strong results and the company's return to net income significantly boosted investor confidence.
2. Raised Full-Year 2025 Guidance: Following its strong Q3 performance, Guardian Pharmacy Services raised its full-year 2025 revenue guidance to a range of $1.43 billion to $1.45 billion and its adjusted EBITDA guidance to $104 million to $106 million, indicating confidence in continued growth.
Show more
1. Strong Q3 2025 Financial Performance: Guardian Pharmacy Services reported robust third-quarter 2025 results on November 10, 2025, with revenue of $377.4 million, a 20% increase year-over-year, exceeding analyst expectations. The company also saw its adjusted EBITDA grow by 19% to $27.3 million, and its resident count increased by 13% to approximately 204,000. These strong results and the company's return to net income significantly boosted investor confidence.
2. Raised Full-Year 2025 Guidance: Following its strong Q3 performance, Guardian Pharmacy Services raised its full-year 2025 revenue guidance to a range of $1.43 billion to $1.45 billion and its adjusted EBITDA guidance to $104 million to $106 million, indicating confidence in continued growth.
Show more
Stock Movement Drivers
Fundamental Drivers
The 1.0% change in GRDN stock from 10/31/2025 to 1/20/2026 was primarily driven by a 4.8% change in the company's Total Revenues ($ Mil).| 10312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 28.04 | 28.32 | 1.00% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1326.60 | 1389.64 | 4.75% |
| P/S Multiple | 1.31 | 1.27 | -3.46% |
| Shares Outstanding (Mil) | 62.05 | 62.12 | -0.13% |
| Cumulative Contribution | 1.00% |
Market Drivers
10/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| GRDN | 1.0% | |
| Market (SPY) | -0.7% | 29.5% |
| Sector (XLV) | 7.7% | 37.0% |
Fundamental Drivers
The 35.5% change in GRDN stock from 7/31/2025 to 1/20/2026 was primarily driven by a 29.6% change in the company's Total Revenues ($ Mil).| 7312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 20.90 | 28.32 | 35.50% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1072.66 | 1389.64 | 29.55% |
| Net Income Margin (%) | 2.33% | 2.90% | 24.32% |
| P/E Multiple | 50.90 | 43.72 | -14.10% |
| Shares Outstanding (Mil) | 60.84 | 62.12 | -2.10% |
| Cumulative Contribution | 35.44% |
Market Drivers
7/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| GRDN | 35.5% | |
| Market (SPY) | 7.5% | 24.1% |
| Sector (XLV) | 19.7% | 17.1% |
Fundamental Drivers
The 24.2% change in GRDN stock from 1/31/2025 to 1/20/2026 was primarily driven by a 381.9% change in the company's Net Income Margin (%).| 1312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 22.81 | 28.32 | 24.16% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 989.20 | 1389.64 | 40.48% |
| Net Income Margin (%) | 0.60% | 2.90% | 381.90% |
| P/E Multiple | 233.49 | 43.72 | -81.27% |
| Shares Outstanding (Mil) | 60.84 | 62.12 | -2.10% |
| Cumulative Contribution | 24.10% |
Market Drivers
1/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| GRDN | 24.2% | |
| Market (SPY) | 13.6% | 30.3% |
| Sector (XLV) | 7.2% | 29.5% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 1/20/2026| Return | Correlation | |
|---|---|---|
| GRDN | ||
| Market (SPY) | 72.9% | 26.7% |
| Sector (XLV) | 22.0% | 26.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GRDN Return | - | - | - | 27% | 49% | -10% | 69% |
| Peers Return | � | � | � | � | � | � | � |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| GRDN Win Rate | - | - | - | 75% | 67% | 0% | |
| Peers Win Rate | � | � | � | � | � | � | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| GRDN Max Drawdown | - | - | - | 0% | -10% | -10% | |
| Peers Max Drawdown | � | � | � | � | � | � | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | 0% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACHC, AMTU, MCTA, PARK, HCA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/20/2026 (YTD)
How Low Can It Go
GRDN has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to ACHC, AMTU, MCTA, PARK, HCA
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities (“LTCFs”) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We emphasize high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities (“ALFs”), and behavioral health facilities and group homes (collectively “BHFs”). More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs, which are our target markets, while the remainder has been generated primarily from residents of skilled nursing facilities (“SNFs”). Additionally, our robust capabilities enable us to serve residents in all types of LTCFs. We are a trusted partner to residents, LTCFs and health plan payors because we help reduce errors in drug administration, manage and ensure adherence to drug regimens, and lower overall healthcare costs. As of June 30, 2024, our 50 pharmacies served approximately 174,000 residents in approximately 6,700 LTCFs across 36 states. Within the U.S. LTCF market, we believe the ALF and BHF sectors present the most attractive opportunity and have the highest growth potential for our business. Certain characteristics of ALFs and BHFs, which are not typical of SNFs, create additional challenges and complexities for pharmacy service providers that Guardian is well suited to address. First, residents at ALFs are typically on a variety of different pharmacy benefit plans, each with a distinct formulary and reimbursement process, covering their complex drug regimens. Second, ALFs often lack staff with formal clinical training and usually do not have an on-site medical director or full-time nurse. Because residents of ALFs rely on off-site physicians to oversee and monitor their health conditions, there is an increased need for coordination among ALF operators, each resident’s physicians and pharmacy service providers. Third, residents in these facilities have the right to choose their own pharmacy, which often leads to multiple pharmacy service providers serving a single ALF. We believe that Guardian enjoys a strong competitive position as a large and purpose-built provider of pharmacy services to ALFs and BHFs. We offer a variety of services that we believe address the challenges that ALFs and BHFs face, and differentiate us from our competitors, providing residents, LTCFs and health plan payors with a compelling value proposition. Our centralized corporate support capabilities empower our local pharmacy operators to offer an extensive suite of high-touch, individualized, consultative pharmacy services, using a portfolio of proprietary data analytics systems and technology designed to help ensure that the right dose of the right medication is provided to the right resident at the right time. Examples of our specialized services include: • Assisting residents in optimizing pharmacy benefit plan coverage of their medication by coordinating formulary interchanges with residents’ physicians; • Proactively analyzing potential adverse drug interactions and managing potential risks in medication administration; • Providing robotic dispensing and customized compliance solutions, organized by resident and time of administration; • Integrating a resident’s drug regimen with the LTCF’s Electronic Medication Administration Records (“EMARs”) to help ensure adherence; • Providing training for LTCF caregivers to help them administer medications to residents more safely, efficiently and cost-effectively; • Partnering with LTCF operators to increase the number of residents using our services at each facility we serve, which we refer to as “resident adoption,” in order to streamline drug administration and minimize medication management risk; • Conducting mock audits of LTCFs to monitor compliance with drug administration and government regulation; and • Reviewing periodically the drug regimen for each resident by consulting pharmacists. --- We were originally formed as Guardian Pharmacy, LLC, an Indiana limited liability company, on July 21, 2003. On November 16, 2021, we formed Guardian Pharmacy Services, Inc., or Guardian Inc., as a direct, wholly owned subsidiary of Guardian Pharmacy, LLC. As a result of the Corporate Reorganization, Guardian Inc. will be a holding company and the sole manager of Guardian Pharmacy, LLC, with no material assets other than its 100% interest in Guardian Pharmacy, LLC; and Guardian Pharmacy, LLC will wholly own and be the sole member of each of the Converting Subsidiaries. In addition, Guardian Pharmacy, LLC will continue to be the majority owner of each of the Non-Converting Subsidiaries. Our principal executive offices are located at 300 Galleria Parkway SE, Suite 800, Atlanta, Georgia.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Guardian Pharmacy Services (GRDN):
- It's like a B2B CVS or Walgreens, providing comprehensive pharmacy services exclusively for long-term care facilities and nursing homes, rather than individual consumers.
- Think of it as the Aramark or Sodexo of pharmacy services, managing medication needs for institutional clients like assisted living facilities and other healthcare settings.
AI Analysis | Feedback
- Medication Dispensing: Providing prescription fulfillment and specialized packaging of medications tailored for residents in long-term care facilities.
- Consultant Pharmacist Services: Offering expert review of medication regimens for residents to optimize therapeutic outcomes and ensure patient safety and compliance.
- Medication Management Solutions: Supplying specialized packaging, automated dispensing systems, and technology to assist long-term care facilities with efficient medication administration.
- Delivery and Logistics: Ensuring timely and secure delivery of medications directly to long-term care facilities through dedicated courier services.
- Clinical and Educational Support: Providing ongoing clinical guidance, staff training, and formulary management to long-term care facility personnel.
AI Analysis | Feedback
Guardian Pharmacy Services (GRDN) primarily sells its specialized pharmacy services to other companies, specifically a wide range of long-term care facilities.
Due to the nature of their business model, which involves serving a fragmented market of numerous individual facilities, there are no specific publicly disclosed "major customers" that are large, publicly traded companies whose names and symbols could be listed. GRDN's customer base consists of thousands of facilities across various categories, which are their direct customers:
- Skilled nursing facilities
- Assisted living facilities
- Hospice providers
- Intermediate care facilities for individuals with intellectual and developmental disabilities
These facilities are typically independent, privately owned, or part of smaller, regional chains, rather than large, publicly traded corporations that would constitute a concentrated customer base for GRDN.
AI Analysis | Feedback
null
AI Analysis | Feedback
Fred Burke, President & CEO
Fred Burke is the Co-founder, President, and CEO of Guardian Pharmacy Services, which he started 20 years ago. Prior to Guardian, he co-founded Central Pharmacy Services, Inc. (CPSI), a nuclear pharmacy company, which grew to 45 business units and was acquired by Cardinal Health in 2001. He also co-founded Sales Technologies, Inc., which was acquired by The Dun & Bradstreet Corporation in 1989. Burke previously worked as a consultant with McKinsey & Company and a Brand Manager with Procter & Gamble. He is also a Co-founder and Chairman of the Senior Care Pharmacy Coalition (SCPC).
David Morris, EVP & CFO
David Morris is a Co-founder, EVP, and CFO of Guardian Pharmacy Services. His expertise in financial strategy, management, and risk management has been crucial to the company's growth. Morris was previously the CFO of Central Pharmacy Services and President of the PBM Division at Complete Health, where he established and operated Rx Management, a subsidiary PBM division. He emphasizes a patient, steady approach to growth and has been involved in multiple successful companies over a 30-year career.
Kendall Forbes, EVP, Sales & Operations
Kendall Forbes is a Co-founder and EVP of Sales & Operations at Guardian Pharmacy Services, with over 35 years of experience in the pharmacy industry. He was also a Co-founder and EVP of Sales and Operations for Central Pharmacy Services, Inc. Forbes has been instrumental in the growth of Guardian, responsible for developing operational and strategic plans, launching 37 greenfield start-up pharmacies, and integrating 8 acquisitions.
Doug Towns, Vice President & General Counsel
Doug Towns serves as Vice President and General Counsel for Guardian Pharmacy Services. He has a long-standing working partnership with Guardian's executive team that dates back to 1995. Before joining Guardian in 2016, Towns spent nearly two decades as a Partner with Jones Day in Atlanta.
David Martin, Vice President, IT & Operational Systems
David Martin is the Vice President, IT & Operational Systems at Guardian Pharmacy Services, joining the company in 2012. He has an extensive background in technology leadership roles, including serving as a Senior IT Consultant with IBM for three years and nine years with Allconnect, Inc., where he rose to the level of Vice President of Technology & Software Development.
AI Analysis | Feedback
Guardian Pharmacy Services (NYSE: GRDN) faces several key risks to its business operations.Key Risks
- Inflation and Limited Pricing Control: Guardian Pharmacy Services' business is significantly exposed to inflationary pressures without the ability to fully offset them through price increases. The majority of residents in assisted living facilities, which Guardian serves, rely on Medicare Part D, with pricing largely dictated by the federal government and pharmacy benefit managers (PBMs). This limits Guardian's direct control over pricing, making it challenging to maintain margins in an inflationary environment.
- Government and Regulatory Changes: The company operates in a heavily regulated healthcare industry. Changes in federal agencies, healthcare finances, and regulations, particularly those aimed at lowering pharmaceutical costs and limiting pharmacy reimbursements, could materially impact Guardian's business model and financial performance.
- Competition and Maintaining Key Relationships: The long-term care facility (LTCF) institutional pharmacy market is competitive, with Guardian operating alongside national providers, regional players, and numerous independent pharmacies. The company's success depends on its ability to effectively market and sell its services, maintain and expand relationships with LTCF operators on favorable terms, and manage its relationships with pharmaceutical wholesalers, manufacturers, and health plan payors.
AI Analysis | Feedback
null
AI Analysis | Feedback
Guardian Pharmacy Services (symbol: GRDN) operates primarily in the institutional and long-term care pharmacy market in the United States. The company provides technology-enabled services including clinical, drug dispensing, and administration capabilities to long-term care facilities, such as assisted living facilities, behavioral health facilities, group homes, and other post-acute and long-term care settings. The addressable market sizes for Guardian Pharmacy Services' main products and services in the U.S. are as follows:- For Institutional Pharmacies in the U.S., the market size was estimated at $24.8 billion in 2024.
- The long-term care pharmacy market in the U.S. is estimated to be approximately $18-$19 billion, with national long-term care pharmacies holding over 90% of the market share. This market is projected to grow to approximately $22.8 billion in 2025.
AI Analysis | Feedback
Expected drivers of future revenue growth for Guardian Pharmacy Services (symbol: GRDN) over the next 2-3 years include strategic acquisitions, organic expansion fueled by an increasing resident count, the expanding long-term care (LTC) market, and enhanced operational efficiency through technology integration.
Drivers of Future Revenue Growth:
- Strategic Acquisitions and Geographic Expansion: Guardian Pharmacy Services consistently pursues growth through strategic acquisitions, expanding its presence into new states and strengthening its footprint in existing markets. Recent examples include the acquisition of Mercury Pharmacy Services in Washington in June 2025, Managed Healthcare Pharmacy in Oregon and Washington in August 2025, and Senior Care Pharmacy in Kansas in May 2025. The company actively seeks "high-performing local partners in regions with unmet needs" and has an "active M&A pipeline", enabling it to enter new geographic areas and increase its overall resident count. This strategy has contributed to its expansion to over 50 pharmacies serving approximately 7,000 LTC facilities nationwide.
- Organic Growth and Increasing Resident Count: Beyond acquisitions, Guardian Pharmacy Services also focuses on organic expansion and "greenfield startups". The company reported a 15% year-over-year increase in its resident count for Q1 2025, a metric directly correlated with recurring revenue streams. This organic growth, alongside strategic acquisitions, contributes significantly to its overall expansion strategy.
- Growing Demand in the Long-Term Care (LTC) Market: The broader long-term care pharmacy services market is experiencing substantial growth, driven by an aging population and a rising preference for home-based care. The market is projected to grow at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2032, reaching an estimated value of $38.7 billion by 2032. Guardian Pharmacy Services is well-positioned to capitalize on this demographic trend and the increasing need for specialized medication management services within LTC facilities.
- Operational Efficiency and Technology Integration: The company's unique "local-autonomy business model" empowers local pharmacy teams to prioritize customer service, while a centralized corporate support team manages complex operational aspects such as IT, data analytics, and human resources. Guardian Pharmacy Services is also investing in advanced pharmacy management software, automated dispensing systems, and data analytics tools, which enhance efficiency, reduce medication errors, and improve patient care, leading to potential cost savings and increased profitability. The industry-wide focus on patient safety, quality care, and reducing hospital readmissions also encourages greater investment in pharmacy-led medication management programs, further driving demand for specialized LTC pharmacy services.
AI Analysis | Feedback
Share Repurchases
- In May 2025, Guardian Pharmacy Services completed a "Synthetic Secondary" transaction involving the repurchase of 1,440,447 shares of Class A common stock at $21.00 per share, using net proceeds from an equivalent number of newly issued shares, thus maintaining the total number of outstanding shares.
- Concurrently in May 2025, the company entered into stock purchase agreements to privately repurchase up to 1,457,365 shares of its Class A common stock, which were originally converted from Class B stock during a September 2024 corporate reorganization.
Share Issuance
- Guardian Pharmacy Services completed its Initial Public Offering (IPO) in September 2024, issuing 8,000,000 shares of Class A common stock at $14.00 per share, which raised $112 million.
- As part of a public offering in May 2025, Guardian issued 1,440,447 new shares of Class A common stock, although these were immediately repurchased in a non-dilutive "synthetic secondary" transaction.
- In October 2025, the company filed a shelf registration statement for the possible future issuance and sale of up to 1,020,000 shares of Class A common stock.
Inbound Investments
- The company's Initial Public Offering (IPO) in September 2024 generated $112 million from the sale of 8,000,000 shares of Class A common stock.
- Prior to becoming a public company, Guardian received significant capital investments from Cardinal Equity Partners and its co-founders.
Outbound Investments
- Guardian Pharmacy Services actively pursued strategic acquisitions, including Heartland Pharmacy (April 2024), Freedom Pharmacy (November 2024), Senior Care Pharmacy in Wichita, Kansas (April 2025), and Managed Healthcare Pharmacy in Oregon (August 2025).
- These acquisitions contributed to a 14% annual increase in residents under management by the fourth quarter of 2024.
- The company expanded its network through new "greenfield" pharmacies, such as one launched in Naples, Florida, in April 2025.
Capital Expenditures
- Capital expenditures primarily support Guardian Pharmacy Services' growth strategy by funding the launch of new greenfield pharmacies and the integration of acquired pharmacies.
- The company aims to ensure sufficient liquidity and financial resources to cover its future operating expenses and capital expenditure requirements.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Guardian Pharmacy Services
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.96 |
| Mkt Cap | 1.5 |
| Rev LTM | 3,266 |
| Op Inc LTM | 444 |
| FCF LTM | 68 |
| FCF 3Y Avg | 54 |
| CFO LTM | 335 |
| CFO 3Y Avg | 308 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.4% |
| Rev Chg 3Y Avg | 9.0% |
| Rev Chg Q | 6.4% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Mgn LTM | 13.6% |
| Op Mgn 3Y Avg | 15.0% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 10.3% |
| CFO/Rev 3Y Avg | 10.2% |
| FCF/Rev LTM | 4.9% |
| FCF/Rev 3Y Avg | 4.6% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA218080 | LEVETIRACETAM | levetiracetam | solution | 11212025 | -0.1% | -0.1% | -0.1% | -0.1% | -0.1% |
| ANDA216149 | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | capsule, delayed release | 3152023 | |||||
| ANDA214541 | LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | loperamide hydrochloride | tablet | 5272021 | |||||
| ANDA210755 | IBUPROFEN | ibuprofen | suspension/drops | 9262018 | |||||
| ANDA210149 | IBUPROFEN | ibuprofen | suspension | 8172018 | |||||
| ANDA209215 | GUAIFENESIN | guaifenesin | tablet, extended release | 9062017 | |||||
Price Behavior
Price Behavior
| Market Price | $28.32 | |
| Market Cap ($ Bil) | 1.8 | |
| First Trading Date | 09/26/2024 | |
| Distance from 52W High | -10.2% | |
| 50 Days | 200 Days | |
| DMA Price | $29.87 | $21.12 |
| DMA Trend | up | up |
| Distance from DMA | -5.2% | 34.1% |
| 3M | 1YR | |
| Volatility | 39.8% | 46.6% |
| Downside Capture | 167.54 | 99.24 |
| Upside Capture | 185.39 | 117.77 |
| Correlation (SPY) | 40.1% | 31.6% |
GRDN Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.73 | 1.48 | 1.15 | 1.07 | 0.75 | 0.36 |
| Up Beta | -0.04 | 0.71 | 1.79 | 1.71 | 0.66 | 0.47 |
| Down Beta | 1.44 | 0.49 | 0.77 | 0.71 | 0.45 | 0.71 |
| Up Capture | 252% | 256% | 154% | 147% | 130% | 23% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 11 | 22 | 33 | 69 | 133 | 170 |
| Down Capture | 172% | 169% | 90% | 67% | 95% | 65% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 11 | 19 | 31 | 57 | 116 | 144 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullReturns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | 5.0% | -4.8% | 4.8% |
| 8/11/2025 | 13.8% | 24.8% | 45.8% |
| 5/12/2025 | -4.0% | 3.4% | -21.4% |
| 3/3/2025 | -5.4% | -7.7% | 6.3% |
| 11/12/2024 | -10.7% | -2.8% | 13.5% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 4 |
| # Negative | 3 | 3 | 1 |
| Median Positive | 9.4% | 14.1% | 9.9% |
| Median Negative | -5.4% | -4.8% | -21.4% |
| Max Positive | 13.8% | 24.8% | 45.8% |
| Max Negative | -10.7% | -7.7% | -21.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/10/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/11/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/12/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/26/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/12/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 09/16/2024 | 424A (06/30/2024) |
| 06/30/2023 | 10/03/2023 | S-1 (06/30/2023) |
| 03/31/2023 | 07/12/2023 | DRS/A (03/31/2023) |
| 09/30/2021 | 11/22/2021 | DRS/A (09/30/2021) |
| 03/31/2021 | 07/23/2021 | DRS/A (03/31/2021) |
| 12/31/2019 | 04/03/2020 | DRS/A (12/31/2019) |
| 09/30/2019 | 02/13/2020 | DRS (09/30/2019) |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cosler, Steven D | Direct | Buy | 12052025 | 29.61 | 3,370 | 99,786 | 739,776 | Form | |
| 2 | Cardinal, Equity Fund, Lp | Direct | Sell | 9302025 | 20.16 | 270,958 | 5,462,513 | 4,033,996 | Form | |
| 3 | Cardinal, Equity Fund, Lp | Direct | Sell | 9302025 | 20.16 | 50,305 | 1,014,149 | 3,019,847 | Form | |
| 4 | Pharmacy, Investors, Llc | Direct | Sell | 9302025 | 20.16 | 813,318 | 16,396,491 | 12,108,540 | Form | |
| 5 | Pharmacy, Investors, Llc | Direct | Sell | 9302025 | 20.16 | 150,998 | 3,044,120 | 9,064,420 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.